ClinicalTrials.gg
CompletedNCT04950764Updated May 4, 2026Results posted

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

A Phase 1 interventional study of Seladelpar in Primary Biliary Cholangitis, Compensated Cirrhosis and Hepatic Impairment, sponsored by Gilead Sciences. Completed at 20 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
10th of 10
24 · median 126
Started
2021
with 1 other
Phase 1
Only one
of the 10
Registered
7th of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is the only one in phase 1, and was the 7th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Participants with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

03

Conditions studied

  • Primary Biliary Cholangitis
  • Compensated Cirrhosis
  • Hepatic Impairment

Keywords

  • PBC
  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females between 18 and 80 years of age (inclusive) who are able to comprehend instructions and follow the study procedures and are willing to sign an Form (ICF)
  2. Females of who are sexually active with a non-sterile male partner (sterile male partners are defined as men vasectomized since at least 6 months) must be willing to use the methods throughout the study and for 30 days after study drug administration.
  3. For at least 90 days after study drug administration, non-vasectomized males must not donate sperm, be willing to use contraception with childbearing potential partners and any male participant with a pregnant partner must use a condom.
  4. Willing to abstain from consuming grapefruit, pomelo, star fruit, or Seville orange containing products from 7 days prior to dose of study medication through day of discharge.
  5. Confirmed diagnosis of PBC with evidence of cirrhosis and classification of CP-A, CP-A + PHT, CP-B or CP-C
  6. Screening laboratory parameters:

    • Alkaline phosphatase (ALP), (ALT) and aspartate aminotransferase (AST) \< 10 × (ULN)
    • Total ≤ 5 × ULN
  7. Ursodeoxycholic acid (UDCA) for a minimum of 12 weeks of treatment prior to Day 1
  8. At screening confirmed diagnosis of PBC
  9. Model for end-stage liver disease (MELD)-Na scores of 6 to 24

Exclusion criteria

Exclusion Criteria:

  1. or history of acute or chronic liver disease of an etiology other than PBC
  2. Patients with a diagnosis of overlapping PBC and hepatitis
  3. History, evidence, or high suspicion of hepatobiliary based on imaging, screening laboratory values, and/or clinical symptoms.
  4. Presumptive or diagnosed infection that requires systemic therapy within 12 weeks of Screening and through Day 1
  5. Female participants who are pregnant or nursing
  6. Screening (ECG) that demonstrates a ≥ 500 msec, or any other significant ECG finding with clinically significant abnormalities as determined by the Investigator
  7. Positive for surface antigen (HBsAg), virus - ribonucleic acid (HCV RNA), or anti (HIV) antibody
  8. Any non-hepatic acute or chronic condition that, in the opinion of the Investigator, would limit the patient's ability to complete and/or participate in the study or compromise the integrity of the data
  9. Has experienced an illness that is considered by the Investigator to be clinically significant within 2 weeks before administration of product
  10. Clinically relevant drug or alcohol abuse within 6 months of Screening. A positive drug screen will exclude participants unless it can be explained by a prescribed medication
  11. Use of obeticholic acid (OCA), any drug of the same class, or fibrates (e.g., bezafibrate, fenofibrate, elafibranor, lanifibranor, pemafibrate, saroglitizar) within 30 days of Baseline
  12. Use of an experimental or unapproved treatment for PBC within 30 days of Baseline
  13. Clinically evident complication(s) of cirrhosis and portal hypertension that required either emergency room visit, hospital admission or both during the 12 week period prior to investigational product administration

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)

    Participants with primary biliary cholangitis (PBC) and a Child-Pugh (CP) classification of CP-A (score 5 to 6) without portal hypertension (PHT) will receive a single dose of seladelpar 10 mg, orally, on Day 1.

    Drug: Seladelpar

  • Experimental
    Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)

    Participants with PBC and a CP classification of CP-A (score 5 to 6) with PHT will receive a single dose of seladelpar 10 mg, orally, on Day 1.

    Drug: Seladelpar

  • Experimental
    Part A: Cohort 3 - CP-B (Seladelpar 10 mg)

    Participants with PBC and a CP classification of CP-B (score 7 to 9) will receive a single dose of seladelpar 10 mg, orally, on Day 1.

    Drug: Seladelpar

  • Experimental
    Part A: Cohort 4 - CP-C (Seladelpar 10 mg)

    Participants with PBC and a CP classification of CP-C (score 10 to 12) will receive a single dose of seladelpar 10 mg, orally, on Day 1.

    Drug: Seladelpar

  • Experimental
    Experimental: Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg or 10 mg)

    Participants with PBC and a CP classification of CP-A (score 5 to 6) with PHT, who complete Part A, will receive seladelpar 10 mg or 5 mg, orally, once daily, for 28 days. Doses for Part B will be chosen based on exposure from a single dose in Part A for individual participants.

    Drug: Seladelpar

  • Experimental
    Experimental: Part B: Cohort 3 - CP-B (Seladelpar 5 mg or 10 mg)

    Participants with PBC and a CP classification of CP-B (score 7 to 9), who complete Part A, will receive seladelpar 10 mg or 5 mg, orally, once daily, for 28 days. Doses for Part B will be chosen based on exposure from a single dose in Part A for individual participants.

    Drug: Seladelpar

Interventions

  • Tablets Administered Orally

    Also known as: Livdelzi®

06

What researchers measure

Primary outcomes

  1. Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)

    Cmax is defined as the maximum observed plasma concentration of the study drug.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  2. Part A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)

    Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  3. Part A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

    AUC0-t is defined as area under the concentration--time curve from time zero to the last measurable concentration.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  4. Part A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)

    AUC0-inf is defined as area under the concentration--time curve from time zero extrapolated to infinity, calculated as AUC0-t+Ct/Kel, where: Ct = the last measurable concentration and Kel = elimination rate constant.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  5. Part B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)

    Cmax is defined as the maximum observed plasma concentration of the study drug.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  6. Part B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)

    Cmax,ss is defined as the steady-state maximum observed plasma concentration of the study drug at Day 28.

    Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  7. Part B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)

    Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  8. Part B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)

    Tmax,ss is defined as the steady-state time to reach maximum observed plasma concentration of the study drug at Day 28.

    Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  9. Part B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)

    AUC0-24 is defined as area under the concentration-time curve from time zero to 24 hours.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  10. Part B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)

    AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.

    Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  11. Part B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)

    RCmax is defined as the accumulation ratio based on Cmax, calculated as Cmax on Day 28/ Day 1.

    Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  12. Part B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

    RAUC0-t is defined as the accumulation ratio based on AUC0-t, calculated as AUC0-tau on Day 28/ AUC0-24 on Day 1 for participants with dose once a day.

    Time frame: Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  13. Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs

    An adverse event (AE) was defined as any medical occurrence in a participant administered to a pharmaceutical product in a clinical study, regardless of a causal relationship with this treatment. TEAEs were defined as AEs that commenced or worsened on or after the time of study drug administration in Part A until up to 30 days after study drug administration in Part A or before the first study drug administration in Part B (whichever is earlier). For Part B, TEAEs are defined as AEs that commence or worsen on or after the time of first study drug administration in Part B until up to 30 days after the last study drug administration in Part B. A drug-related TEAE was defined as TEAE which was related (reported as 'possible', 'probable', or 'definite') to study drug. Percentages were rounded off.

    Time frame: Part A: Up to Week 5; Part B: Up to Week 8

  14. Percentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEs

    TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced. The percentage of participants with any severity grade and severity grade of 3 or 4 were reported. Percentages were rounded off.

    Time frame: Part A: Up to Week 5; Part B: Up to Week 8

  15. Percentage of Participants Who Experienced TEAEs of Special Interest

    TEAEs of special interest for this study were defined as AEs that met CTCAE version 5.0 or the most recent version Grade 2 criteria or higher for AEs of elevated alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine kinase, lipase, or serum creatinine. Hepatic decompensation clinical events including ascites, jaundice, esophageal variceal bleeding, and hepatic encephalopathy, were also defined as TEAEs of special interest for this study. Percentages were rounded off.

    Time frame: Part A: Up to Week 5; Part B: Up to Week 8

  16. Percentage of Participants With Clinically Significant Changes in Vital Signs

    Vital signs (including oral temperature, respiratory rate, seated blood pressure \[diastolic and systolic\], and heart rate) were evaluated. Percentage of participants with clinically significant changes in vital signs evaluations was reported. The clinically significant changes were based on investigator's judgement.

    Time frame: Part A: Up to Day 4; Part B: Up to Day 31

  17. Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings

    ECG measurements included the parameters of heart rate, ventricular rate, PR interval, QRS duration, QT interval (uncorrected), and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Per protocol, ECG findings were classified in 1 of 3 categories: normal, abnormal but not clinically significant, or abnormal and clinically significant. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.

    Time frame: Part A: Up to Day 4; Part B: Up to Day 28

  18. Percentage of Participants Who Experienced Laboratory Abnormalities

    Clinical laboratory parameters included biochemistry, hematology, coagulation, and urinalysis. Abnormal laboratory values were graded according to the NCI CTCAE version 5.0.Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. The percentage of participants with a shift of ≥ 2 NCI CTCAE grade from baseline was reported.

    Time frame: Part A: Up to Day 4; Part B: Up to Day 31

Secondary outcomes

  1. Part A: PK Parameter (Urine): Ae0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

    Ae0-t is defined as the cumulative urinary excretion from time zero to time t, calculated as the sum of the amounts excreted over each collection interval.

    Time frame: Day 1: Predose; 0-6 h, and 6-12 h postdose

  2. Part A: PK Parameter (Urine): CLR of Seladelpar

    CLR is defined as the renal clearance, calculated as Ae0-t / AUC0-12.

    Time frame: Day 1: Predose; 0-6 h, and 6-12 h postdose

  3. Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between Cmax and Baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  4. Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  5. Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  6. Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between Cmax and Baseline Bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  7. Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  8. Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  9. Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between Cmax and Baseline Prothrombin Time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  10. Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Prothrombin Time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  11. Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Prothrombin Time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  12. Part A: Rsq Between Plasma Seladelpar Cmax and CP Score

    Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  13. Part A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score

    Rsq is defined as the R-squared value for the regression between AUC0-inf and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  14. Part A: Rsq Between Plasma Seladelpar AUC0-t and CP Score

    Rsq is defined as the R-squared value for the regression between AUC0-t and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose

  15. Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between Cmax and baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  16. Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between AUC0-t and baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  17. Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin

    Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline Albumin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  18. Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between Cmax and baseline prothrombin time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  19. Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between AUC0-t and baseline prothrombin time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  20. Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time

    Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline prothrombin time.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  21. Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between Cmax and baseline bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  22. Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between AUC0-t and baseline bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  23. Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin

    Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline bilirubin.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  24. Part B: Rsq Between Plasma Seladelpar Cmax and CP Score

    Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

  25. Part B: Rsq Between Plasma Seladelpar AUC0-t and CP Score

    Rsq is defined as the R-squared value for the regression between AUC0-t and and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose

  26. Part B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score

    Rsq is defined as the R-squared value for the regression between AUC0-inf and and CP score of participants.

    Time frame: Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose

07

Results

Posted May 4, 2026

Participant flow

Participants were enrolled at study sites in the United States, South Korea, Spain, and the United Kingdom.

Part A
Participant flow — Part A
MilestonePart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Started66660000
Completed66660000
Not completed00000000
Part B
Participant flow — Part B
MilestonePart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Started00001515
Completed00001515
Not completed00000000

Outcome measures

PrimaryPart A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)

Cmax is defined as the maximum observed plasma concentration of the study drug.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Mean · nanograms per milliliter (ng/mL)
Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)
nanograms per milliliter (ng/mL)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
Cmax of Seladelpar182.0 ± 60.68367.7 ± 238.28359.2 ± 158.61388.5 ± 153.45
Cmax of M120.08 ± 9.01233.17 ± 9.91347.27 ± 22.43940.07 ± 12.974
Cmax of M2225.3 ± 117.66257.7 ± 30.58291.7 ± 92.68217.7 ± 36.58
Cmax of M342.55 ± 20.51028.78 ± 6.73934.50 ± 10.99423.88 ± 9.182
Statistical analysis
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 183 · 90% CI 114 to 295Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 189 · 90% CI 125 to 288Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 210 · 90% CI 144 to 306Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 172 · 90% CI 118 to 250Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 233 · 90% CI 148 to 366Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 205 · 90% CI 137 to 308Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 125 · 90% CI 87.6 to 179Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 138 · 90% CI 91.7 to 207Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 105 · 90% CI 72.4 to 153Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 73.2 · 90% CI 48.7 to 110Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 86.3 · 90% CI 55.9 to 133Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 58.4 · 90% CI 36.5 to 93.3Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
PrimaryPart A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)

Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Median · hours (h)
Part A: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)
hours (h)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
Tmax of Seladelpar1.208 (0.500 to 2.500)0.758 (0.500 to 6.000)1.250 (0.417 to 3.000)1.250 (0.500 to 2.500)
Tmax of M14.000 (2.417 to 8.000)4.500 (2.017 to 6.000)3.000 (0.417 to 6.000)5.000 (2.517 to 6.000)
Tmax of M25.500 (2.500 to 8.117)4.000 (2.017 to 8.000)4.000 (2.917 to 6.033)8.000 (2.517 to 12.100)
Tmax of M35.500 (4.017 to 12.083)4.500 (2.983 to 8.000)4.500 (2.917 to 6.033)6.000 (3.017 to 24.000)
PrimaryPart A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

AUC0-t is defined as area under the concentration--time curve from time zero to the last measurable concentration.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Mean · h*ng/mL
Part A: PK Parameter: AUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
h*ng/mLPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
AUC0-t of Seladelpar800 ± 2141390 ± 5041390 ± 8121970 ± 416
AUC0-t of M1239 ± 41.3324 ± 117351 ± 151499 ± 287
AUC0-t of M22930 ± 11403730 ± 15704550 ± 30704970 ± 1950
AUC0-t of M3475 ± 106367 ± 143394 ± 75.8368 ± 171
Statistical analysis
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 171 · 90% CI 124 to 235Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 159 · 90% CI 102 to 245Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 249 · 90% CI 189 to 328Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 130 · 90% CI 98.8 to 172Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 139 · 90% CI 101 to 190Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 188 · 90% CI 126 to 279Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 126 · 90% CI 83.9 to 189Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 137 · 90% CI 78.0 to 241Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 162 · 90% CI 97.5 to 269Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 75.4 · 90% CI 55.9 to 102Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 83.6 · 90% CI 66.1 to 106Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 73.7 · 90% CI 51.8 to 105Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
PrimaryPart A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)

AUC0-inf is defined as area under the concentration--time curve from time zero extrapolated to infinity, calculated as AUC0-t+Ct/Kel, where: Ct = the last measurable concentration and Kel = elimination rate constant.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Mean · h*ng/mL
Part A: PK Parameter: AUC0-inf of Seladelpar and Its Metabolites (M1, M2, and M3)
h*ng/mLPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
AUC0-inf of Seladelpar841 ± 2281540 ± 4741440 ± 8292020 ± 443
AUC0-inf of M1272 ± 44.4339 ± 122375 ± 147530 ± 284
AUC0-inf of M23140 ± 11103930 ± 16204660 ± 30905270 ± 2100
AUC0-inf of M3580 ± 63.8416 ± 156495 ± 129404 ± 99.2
Statistical analysis
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 182 · 90% CI 134 to 248Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 157 · 90% CI 102 to 242Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 243 · 90% CI 183 to 322Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 120 · 90% CI 89.0 to 162Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 132 · 90% CI 95.4 to 182Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 178 · 90% CI 117 to 269Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 123 · 90% CI 84.0 to 181Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 131 · 90% CI 75.7 to 226Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 158 · 90% CI 96.2 to 261Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg) · Geometric least-squares mean ratio: 68.8 · 90% CI 50.0 to 94.7Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 3 - CP-B (Seladelpar 10 mg) · Geometric least-squares mean ratio: 83.2 · 90% CI 63.4 to 109Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
  • Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg) vs Part A: Cohort 4 - CP-C (Seladelpar 10 mg) · Geometric least-squares mean ratio: 68.5 · 90% CI 52.7 to 88.9Estimated ratio of model-adjusted geometric means was used to perform comparison. A linear model was fit to the data per parameter. The response variable was the natural-log transformed PK parameter, and the model included cohort as fixed effect.
PrimaryPart B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)

Cmax is defined as the maximum observed plasma concentration of the study drug.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Mean · ng/mL
Part B: PK Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3)
ng/mLPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
Cmax of Seladelpar299.08 ± 182.985344.40 ± 121.04978.40 ± NA229.00 ± NA
Cmax of M133.00 ± 20.90357.18 ± 28.65611.30 ± NA18.20 ± NA
Cmax of M2268.80 ± 138.124255.80 ± 40.58698.60 ± NA181.00 ± NA
Cmax of M324.700 ± 7.19637.860 ± 7.8127.730 ± NA8.330 ± NA
PrimaryPart B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)

Cmax,ss is defined as the steady-state maximum observed plasma concentration of the study drug at Day 28.

Time frame:
Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Mean · ng/mL
Part B: PK Parameter: Cmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)
ng/mLPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
Cmax,ss of Seladelpar260.60 ± 75.255324.00 ± 153.49853.20 ± NA255.00 ± NA
Cmax,ss of M136.320 ± 14.36544.700 ± 21.1348.190 ± NA32.700 ± NA
Cmax,ss of M2326.2 ± 124.20297.2 ± 72.77108.0 ± NA369.0 ± NA
Cmax,ss of M336.140 ± 15.45148.880 ± 18.3118.540 ± NA18.300 ± NA
PrimaryPart B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)

Tmax is defined as the time to reach the maximum observed plasma concentration of the study drug.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Median · h
Part B: PK Parameter: Tmax of Seladelpar and Its Metabolites (M1, M2, and M3)
hPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
Tmax of Seladelpar1.000 (1.000 to 5.000)1.000 (0.467 to 2.483)1.500 (1.500 to 1.500)0.500 (0.500 to 0.500)
Tmax of M15.983 (2.500 to 8.000)2.000 (0.467 to 6.000)8.000 (8.000 to 8.000)2.033 (2.033 to 2.033)
Tmax of M25.983 (4.000 to 8.000)3.500 (2.983 to 6.000)8.000 (8.000 to 8.000)6.000 (6.000 to 6.000)
Tmax of M36.000 (3.533 to 8.000)3.500 (3.000 to 6.000)12.000 (12.000 to 12.000)6.000 (6.000 to 6.000)
PrimaryPart B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)

Tmax,ss is defined as the steady-state time to reach maximum observed plasma concentration of the study drug at Day 28.

Time frame:
Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Median · h
Part B: PK Parameter: Tmax,ss of Seladelpar and Its Metabolites (M1, M2, and M3)
hPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
Tmax,ss of Seladelpar1.000 (0.500 to 2.000)0.566 (0.500 to 1.500)3.500 (3.500 to 3.500)1.033 (1.033 to 1.033)
Tmax,ss of M16.000 (2.500 to 8.000)3.016 (1.000 to 4.000)5.000 (5.000 to 5.000)6.000 (6.000 to 6.000)
Tmax,ss of M26.000 (2.500 to 8.000)3.500 (2.500 to 5.900)12.000 (12.000 to 12.000)6.000 (6.000 to 6.000)
Tmax,ss of M35.000 (4.000 to 8.000)4.000 (2.500 to 6.000)12.000 (12.000 to 12.000)7.917 (7.917 to 7.917)
PrimaryPart B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)

AUC0-24 is defined as area under the concentration-time curve from time zero to 24 hours.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Mean · h*ng/mL
Part B: PK Parameter: AUC0-24 of Seladelpar and Its Metabolites (M1, M2, and M3)
h*ng/mLPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
AUC0-24 of Seladelpar1450 ± 5481053 ± 191814 ± NA1494 ± NA
AUC0-24 of M1346 ± 183338 ± 59167 ± NA209 ± NA
AUC0-24 of M23812 ± 23152892 ± 6491837 ± NA3219 ± NA
AUC0-24 of M3354 ± 134449 ± 85141 ± NA150 ± NA
PrimaryPart B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)

AUCtau is defined as the area under the drug concentration versus time curve over the dosing interval.

Time frame:
Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Mean · h*ng/mL
Part B: PK Parameter: AUC0-tau of Seladelpar and Its Metabolites (M1, M2, and M3)
h*ng/mLPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
AUC0-tau of Seladelpar1329 ± 5171055 ± 380570 ± NA1680 ± NA
AUC0-tau of M1395 ± 270339 ± 121136 ± NA359 ± NA
AUC0-tau of M24377 ± 28603349 ± 15322161 ± NA6415 ± NA
AUC0-tau of M3461 ± 308521 ± 175178 ± NA307 ± NA
PrimaryPart B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)

RCmax is defined as the accumulation ratio based on Cmax, calculated as Cmax on Day 28/ Day 1.

Time frame:
Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Mean · accumulation ratio of Cmax
Part B: PK Parameter: RCmax of Seladelpar and Its Metabolites (M1, M2, and M3)
accumulation ratio of CmaxPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
RCmax of Seladelpar1.121 ± 0.6570.940 ± 0.3000.679 ± NA1.114 ± NA
RCmax of M11.429 ± 1.0560.906 ± 0.3840.725 ± NA1.797 ± NA
RCmax of M21.305 ± 0.3321.158 ± 0.1971.095 ± NA2.039 ± NA
RCmax of M31.445 ± 0.2741.264 ± 0.2491.105 ± NA2.197 ± NA
PrimaryPart B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

RAUC0-t is defined as the accumulation ratio based on AUC0-t, calculated as AUC0-tau on Day 28/ AUC0-24 on Day 1 for participants with dose once a day.

Time frame:
Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Mean · accumulation ratio of AUC0-t
Part B: PK Parameter: RAUC0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
accumulation ratio of AUC0-tPart B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)
RAUC0-t of Seladelpar0.957 ± 0.2581.014 ± 0.2750.700 ± NA1.124 ± NA
RAUC0-t of M11.130 ± 0.3830.999 ± 0.2860.811 ± NA1.720 ± NA
RAUC0-t of M21.222 ± 0.5211.145 ± 0.3921.176 ± NA1.993 ± NA
RAUC0-t of M31.253 ± 0.4401.148 ± 0.2961.261 ± NA2.055 ± NA
PrimaryPercentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs

An adverse event (AE) was defined as any medical occurrence in a participant administered to a pharmaceutical product in a clinical study, regardless of a causal relationship with this treatment. TEAEs were defined as AEs that commenced or worsened on or after the time of study drug administration in Part A until up to 30 days after study drug administration in Part A or before the first study drug administration in Part B (whichever is earlier). For Part B, TEAEs are defined as AEs that commence or worsen on or after the time of first study drug administration in Part B until up to 30 days after the last study drug administration in Part B. A drug-related TEAE was defined as TEAE which was related (reported as 'possible', 'probable', or 'definite') to study drug. Percentages were rounded off.

Time frame:
Part A: Up to Week 5; Part B: Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Any TEAEs033.316.70040.0060.0
Study Drug-Related TEAEs000000020.0
PrimaryPercentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEs

TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced. The percentage of participants with any severity grade and severity grade of 3 or 4 were reported. Percentages were rounded off.

Time frame:
Part A: Up to Week 5; Part B: Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Any Grade and Grade 3 or 4 TEAEs
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Any Grade033.316.70040.0060.0
Grade 3 or 40000020.000
PrimaryPercentage of Participants Who Experienced TEAEs of Special Interest

TEAEs of special interest for this study were defined as AEs that met CTCAE version 5.0 or the most recent version Grade 2 criteria or higher for AEs of elevated alanine transaminase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine kinase, lipase, or serum creatinine. Hepatic decompensation clinical events including ascites, jaundice, esophageal variceal bleeding, and hepatic encephalopathy, were also defined as TEAEs of special interest for this study. Percentages were rounded off.

Time frame:
Part A: Up to Week 5; Part B: Up to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced TEAEs of Special Interest
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Percentage of Participants Who Experienced TEAEs of Special Interest0000020.0020.0
PrimaryPercentage of Participants With Clinically Significant Changes in Vital Signs

Vital signs (including oral temperature, respiratory rate, seated blood pressure \[diastolic and systolic\], and heart rate) were evaluated. Percentage of participants with clinically significant changes in vital signs evaluations was reported. The clinically significant changes were based on investigator's judgement.

Time frame:
Part A: Up to Day 4; Part B: Up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Changes in Vital Signs
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Percentage of Participants With Clinically Significant Changes in Vital Signs00000000
PrimaryPercentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings

ECG measurements included the parameters of heart rate, ventricular rate, PR interval, QRS duration, QT interval (uncorrected), and QT interval corrected for heart rate according to Fridericia's formula (QTcF). Per protocol, ECG findings were classified in 1 of 3 categories: normal, abnormal but not clinically significant, or abnormal and clinically significant. Any abnormality in ECG assessments which were deemed clinically significant by the investigator were reported.

Time frame:
Part A: Up to Day 4; Part B: Up to Day 28
Reported as:
Number · percentage of participants
Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Percentage of Participants With Abnormal Clinically Significant 12-Lead Electrocardiogram (ECG) Findings00000000
PrimaryPercentage of Participants Who Experienced Laboratory Abnormalities

Clinical laboratory parameters included biochemistry, hematology, coagulation, and urinalysis. Abnormal laboratory values were graded according to the NCI CTCAE version 5.0.Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. The percentage of participants with a shift of ≥ 2 NCI CTCAE grade from baseline was reported.

Time frame:
Part A: Up to Day 4; Part B: Up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Laboratory Abnormalities
percentage of participantsPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Percentage of Participants Who Experienced Laboratory Abnormalities0016.7000020.0
SecondaryPart A: PK Parameter (Urine): Ae0-t of Seladelpar and Its Metabolites (M1, M2, and M3)

Ae0-t is defined as the cumulative urinary excretion from time zero to time t, calculated as the sum of the amounts excreted over each collection interval.

Time frame:
Day 1: Predose; 0-6 h, and 6-12 h postdose
Reported as:
Mean · ng
Part A: PK Parameter (Urine): Ae0-t of Seladelpar and Its Metabolites (M1, M2, and M3)
ngPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
Ae0-t of Seladelpar1370 ± 10204660 ± 37706460 ± 58303290 ± 2940
Ae0-t of M10.513 ± 0.6340.957 ± 0.3520.976 ± 0.6750.503 ± 0.261
Ae0-t of M20.119 ± 0.0890.363 ± 0.4620.345 ± 0.3140.056 ± 0.059
Ae0-t of M31.17 ± 1.012.24 ± 0.6942.41 ± 1.941.04 ± 0.474
SecondaryPart A: PK Parameter (Urine): CLR of Seladelpar

CLR is defined as the renal clearance, calculated as Ae0-t / AUC0-12.

Time frame:
Day 1: Predose; 0-6 h, and 6-12 h postdose
Reported as:
Mean · L/h
Part A: PK Parameter (Urine): CLR of Seladelpar
L/hPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)
Part A: PK Parameter (Urine): CLR of Seladelpar0.00208 ± 0.0015200.00361 ± 0.0027550.00723 ± 0.0073910.00238 ± 0.002846
SecondaryPart A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin

Rsq is defined as the R-squared value for the regression between Cmax and Baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin0.2033
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin

Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin0.3735
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin

Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin0.3924
SecondaryPart A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between Cmax and Baseline Bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin0.0318
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin0.1810
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin0.2047
SecondaryPart A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between Cmax and Baseline Prothrombin Time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time0.2774
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between AUC0-inf and Baseline Prothrombin Time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time0.6014
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between AUC0-t and Baseline Prothrombin Time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time0.5804
SecondaryPart A: Rsq Between Plasma Seladelpar Cmax and CP Score

Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar Cmax and CP Score
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar Cmax and CP Score0.1092
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score

Rsq is defined as the R-squared value for the regression between AUC0-inf and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-inf and CP Score0.3056
SecondaryPart A: Rsq Between Plasma Seladelpar AUC0-t and CP Score

Rsq is defined as the R-squared value for the regression between AUC0-t and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Number · no unit
Part A: Rsq Between Plasma Seladelpar AUC0-t and CP Score
no unitPart A: Seladelpar 10 mg
Part A: Rsq Between Plasma Seladelpar AUC0-t and CP Score0.3250
SecondaryPart B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin

Rsq is defined as the R-squared value for the regression between Cmax and baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Albumin0.3351NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin

Rsq is defined as the R-squared value for the regression between AUC0-t and baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Albumin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Day 10.0400NA
Day 280.1175NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin

Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline Albumin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Albumin0.0456NA
SecondaryPart B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between Cmax and baseline prothrombin time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Prothrombin Time0.3124NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between AUC0-t and baseline prothrombin time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Prothrombin Time
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Day 10.1934NA
Day 280.3108NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time

Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline prothrombin time.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Prothrombin Time0.2020NA
SecondaryPart B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between Cmax and baseline bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar Cmax and Baseline Bilirubin0.0012NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between AUC0-t and baseline bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-t and Baseline Bilirubin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Day 10.1136NA
Day 280.0805NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin

Rsq is defined as the R-squared value for the regression between AUC0-inf and baseline bilirubin.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar AUC0-inf and Baseline Bilirubin0.0993NA
SecondaryPart B: Rsq Between Plasma Seladelpar Cmax and CP Score

Rsq is defined as the R-squared value for the regression between Cmax and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar Cmax and CP Score
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar Cmax and CP Score0.0118NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-t and CP Score

Rsq is defined as the R-squared value for the regression between AUC0-t and and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose; Day 28: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48, and 72 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-t and CP Score
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Day 10.2036NA
Day 280.1912NA
SecondaryPart B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score

Rsq is defined as the R-squared value for the regression between AUC0-inf and and CP score of participants.

Time frame:
Day 1: Predose; 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours postdose
Reported as:
Number · no unit
Part B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score
no unitPart B: Seladelpar 10 mgPart B: Seladelpar 5 mg
Part B: Rsq Between Plasma Seladelpar AUC0-inf and CP Score0.1901NA

Adverse events

Collected over All-cause Mortality: Up to 31 weeks; Adverse Events: Part A: Up to Week 5; Part B: Up to Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)0/6 (0%)0/6 (0%)0/6 (0%)
Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)0/6 (0%)0/6 (0%)2/6 (33.3%)
Part A: Cohort 3 - CP-B (Seladelpar 10 mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A: Cohort 4 - CP-C (Seladelpar 10 mg)0/6 (0%)0/6 (0%)0/6 (0%)
Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)0/1 (0%)0/1 (0%)0/1 (0%)
Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)0/5 (0%)1/5 (20%)2/5 (40%)
Part B: Cohort 3 - CP-B (Seladelpar 5 mg)0/1 (0%)0/1 (0%)0/1 (0%)
Part B: Cohort 3 - CP-B (Seladelpar 10 mg)0/5 (0%)0/5 (0%)3/5 (60%)
Most frequent serious events
Most frequent serious events
EventPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Generalised oedemaGeneral disorders0/60/60/60/60/11/50/10/5
BronchitisInfections and infestations0/60/60/60/60/11/50/10/5
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPart A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 5 mg)Part B: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part B: Cohort 3 - CP-B (Seladelpar 5 mg)Part B: Cohort 3 - CP-B (Seladelpar 10 mg)
Abdominal pain upperGastrointestinal disorders0/60/60/60/60/11/50/10/5
AscitesGastrointestinal disorders0/60/60/60/60/11/50/10/5
DyspepsiaGastrointestinal disorders0/60/60/60/60/10/50/11/5
EructationGastrointestinal disorders0/60/60/60/60/11/50/10/5
NauseaGastrointestinal disorders0/60/60/60/60/10/50/11/5
Ear infectionInfections and infestations0/60/60/60/60/11/50/10/5
GastroenteritisInfections and infestations0/60/60/60/60/10/50/11/5
Post procedural haematomaInjury, poisoning and procedural complications0/61/60/60/60/11/50/10/5
Procedural painInjury, poisoning and procedural complications0/60/60/60/60/10/50/11/5
Blood urea increasedInvestigations0/60/60/60/60/10/50/11/5

Baseline characteristics

The Safety Analysis Set included all study participants who received any amount of seladelpar.

Age, Categorical
Age, Categorical(Participants)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
<=18 years00000
Between 18 and 65 years654419
>=65 years01225
Age, Continuous
Age, Continuous(years)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
Mean56 ± 4.461 ± 8.057 ± 13.661 ± 7.259 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
Female656522
Male01012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
Hispanic or Latino12126
Not Hispanic or Latino545418
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
American Indian or Alaska Native00000
Asian51107
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White155617
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Part A: Cohort 1 - CP-A Without PHT (Seladelpar 10 mg)Part A: Cohort 2 - CP-A With PHT (Seladelpar 10 mg)Part A: Cohort 3 - CP-B (Seladelpar 10 mg)Part A: Cohort 4 - CP-C (Seladelpar 10 mg)Total
South Korea40105
United States264517
United Kingdom00011
Spain00101
08

Study locations

20 sites
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • University of Colorado Anschutz
    Aurora, Colorado 80045, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Southern Therapy and Advanced Research LLC
    Jackson, Mississippi 39216, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75203, United States
  • American Research Corporation
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research- SA
    San Antonio, Texas 78229, United States
  • Pusan National University Hospital
    Busan, 49241, South Korea
  • Inje University Busan Paik Hospital
    Busan, South Korea
  • Kyungpook National University Hospital
    Daegu, 41944, South Korea
  • Seoul National University Hospital
    Seoul, 3080, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, 3722, South Korea
  • Hospital General Universitario Gregorio Maran
    Madrid, 28007, Spain
  • NIHR BRC Centre for Liver and Gastrointestinal Research Birmingham
    Birmingham, B15 2GW, United Kingdom
  • The Royal Free London NHS Foundation Trust
    London, NW2 2QG, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion and at least 6 months after the FDA and EMA approval

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Feb 2025, 39 months.

Results were first posted in May 2026, 1 year 2 months after primary completion.

Of 15 phase 1 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Jul 6, 2021
StartActual
Nov 16, 2021
Primary completionActual
Feb 24, 2025
CompletionActual
Feb 27, 2025
Results first posted
May 4, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04950764
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 6, 2021
Start date
Nov 16, 2021
Primary completion
Feb 24, 2025
Completion
Feb 27, 2025
Results posted
May 4, 2026
Last update
May 4, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion